NOVARTIS
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of Diclofenac Sodium Gel in Hand Osteoarthritis
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 360
- Registration Number
- NCT00171652
Antiproteinuric Effect of Valsartan and Lisinopril
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 124
- Registration Number
- NCT00171574
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 64
- Registration Number
- NCT00171132
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1018
- Registration Number
- NCT00170963
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00171587
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine Alone
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 936
- Registration Number
- NCT00171002
- Locations
- ๐จ๐ญ
Novartis Pharmaceuticals, Basel, Switzerland
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171418
- Locations
- ๐บ๐ธ
The Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States
๐บ๐ธDrug Research Services, Inc, Metairie, Louisiana, United States
Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 30
- Registration Number
- NCT00171483
- Locations
- ๐บ๐ธ
Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States
๐บ๐ธDepartment of Internal Medicine - Wake Forest University School of Medicine, Winston Salem, North Carolina, United States
๐บ๐ธMiami Research Associates, Miami, Florida, United States
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 445
- Registration Number
- NCT00171145
- Locations
- ๐บ๐ธ
Novartis, East Hanover, New Jersey, United States
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00170768
- Locations
- ๐บ๐ธ
Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States